UIC-2019-103 Method of Use of Mitogen Activated Protein Kinase Kinase (MEK) Inhibitors

Use of Mitogen Activated Protein Kinase Kinase (MEK) inhibitors to treat congenital aniridia: Improves ocular morphology and development. Reduces corneal stromal thickness, scar area, and opacity. Increases ocular function and response to light stimulation. Observed via electroretinography. Effective in both oral and topical formulations. Preliminary evidence indicates that the formulated MEK inhibitor is soluble in poloxamers. Jonathan Gortat jgortat@otm.uic.edu (312) 413-1643

June 2, 2020

Related Blog

Smart, interactive desk

May 8, 2023 No Comments

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Ultra-Cooled Autonomous Container (UAC) for the Transport and Storage of Goods

December 23, 2022 No Comments

Universitat Politècnica de València Background The current health emergency context has challenged technology in various industrial sectors. In particular, the recent manufacture

Mechanical Hamstring™

December 22, 2022 No Comments

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

UIC-2019-103 Method of Use of Mitogen Activated Protein Kinase Kinase (MEK) Inhibitors

Related Blog

Smart, interactive desk

Ultra-Cooled Autonomous Container (UAC) for the Transport and Storage of Goods

Mechanical Hamstring™

Join Our Newsletter